LPTX — Leap Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $31.24m
- $13.11m
Annual balance sheet for Leap Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 52.1 | 115 | 65.5 | 70.6 | 47.2 |
| Net Total Receivables | 0.073 | 1.19 | 2.1 | 0.771 | 0.704 |
| Prepaid Expenses | |||||
| Total Current Assets | 52.3 | 117 | 68 | 71.6 | 48 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.593 | 0.495 | 0.689 | 0.262 | 0.262 |
| Other Long Term Assets | |||||
| Total Assets | 54.4 | 118 | 70.4 | 72.8 | 49.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.37 | 9.99 | 11.2 | 12.7 | 14.1 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.72 | 10 | 11.5 | 12.7 | 14.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 46.7 | 108 | 58.9 | 60.1 | 35 |
| Total Liabilities & Shareholders' Equity | 54.4 | 118 | 70.4 | 72.8 | 49.1 |
| Total Common Shares Outstanding |